Sign In
Buy A
$137.40
+2.36 (+1.75%)
At Close: Jun 03, 2026
Agilent (A) Reliance on International Sales: What Investors Need to Know
10:15am, Monday, 26'th Aug 2024
Evaluate Agilent's (A) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.
Agilent: A 'Buy' Due To Growing Biopharma, PFAS, And Semi
08:44pm, Thursday, 22'nd Aug 2024
Agilent Technologies focuses on growing biopharma, PFAS testing, and advanced materials for semiconductors. Recent acquisitions and divestitures show mixed results, with potential for technological en
Agilent (A) Q3 Earnings & Revenues Beat Estimates, Fall Y/Y
01:51pm, Thursday, 22'nd Aug 2024
Agilent's (A) fiscal third-quarter results reflect weakness across the Pharma, Food, Chemical and Advanced Materials, and Academic and Government markets.
These Analysts Boost Their Forecasts On Agilent After Strong Earnings
12:08pm, Thursday, 22'nd Aug 2024
Agilent Technologies, Inc. A posted better-than-expected third-quarter earnings and issued upbeat fourth-quarter guidance on Wednesday.
A Stock Earnings: Agilent Technologies Beats EPS, Beats Revenue for Q3 2024
08:53pm, Wednesday, 21'st Aug 2024
Agilent Technologies (NYSE: A ) just reported results for the third quarter of 2024. Agilent Technologies reported earnings per share of $1.32.
Agilent Technologies, Inc. (A) Q3 2024 Earnings Call Transcript
08:10pm, Wednesday, 21'st Aug 2024
Agilent Technologies, Inc. (NYSE:A ) Q3 2024 Earnings Conference Call August 21, 2024 4:30 PM ET Company Participants Conference Call Participants Operator Ladies and gentlemen, welcome to the Agilent
Agilent (A) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
07:00pm, Wednesday, 21'st Aug 2024
While the top- and bottom-line numbers for Agilent (A) give a sense of how the business performed in the quarter ended July 2024, it could be worth looking at how some of its key metrics compare to Wa
Agilent Technologies (A) Q3 Earnings and Revenues Beat Estimates
06:15pm, Wednesday, 21'st Aug 2024
Agilent Technologies (A) came out with quarterly earnings of $1.32 per share, beating the Zacks Consensus Estimate of $1.25 per share. This compares to earnings of $1.43 per share a year ago.
Agilent beats quarterly results on strong demand from biotech clients
05:22pm, Wednesday, 21'st Aug 2024
Agilent Technologies on Wednesday beat Wall Street estimates for third-quarter profit and revenue, banking on strong demand for its medical tools and equipment used in clinical studies.
Agilent Reports Third-Quarter Fiscal Year 2024 Financial Results
04:05pm, Wednesday, 21'st Aug 2024
SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today reported revenue of $1.58 billion for the third quarter ended July 31, 2024, a decline of 5.6% reported and 4.4% core(1)
Agilent (A) Boosts LSAG Segment With J&W 5Q GC/MS Columns
11:31am, Tuesday, 20'th Aug 2024
Agilent Technologies (A) launches J&W 5Q GC/MS Columns to address the growing demand for modern laboratories.
Agilent (A) Set to Report Q3 Earnings: What's in the Offing?
11:21am, Monday, 19'th Aug 2024
Agilent's (A) fiscal third-quarter results are likely to reflect strength in the ACG and DGG segments despite the weak LSAG segment.
Wall Street's Insights Into Key Metrics Ahead of Agilent (A) Q3 Earnings
10:17am, Friday, 16'th Aug 2024
Beyond analysts' top -and-bottom-line estimates for Agilent (A), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter en
Analysts Estimate Agilent Technologies (A) to Report a Decline in Earnings: What to Look Out for
11:00am, Wednesday, 14'th Aug 2024
Agilent (A) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Agilent Receives FDA Approval for MAGE-A4 IHC 1F9 pharmDx as a Diagnostic Tool for Use with Newly Approved TCR T-Cell Therapy
08:00am, Friday, 02'nd Aug 2024
SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc., (NYSE: A) today announced that it has received FDA approval for the use of MAGE-A4 IHC 1F9 pharmDx (SK032) as a diagnostic tool to aid
